This article is more than 5 years old. Information may no longer be current.

Investments allow further research, expansion for Regentis Biomaterials

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Regentis Biomaterials Ltd., a manufacturer of hydrogels for tissue regeneration, received $10 million from investors, allowing the company to continue promoting GelrinC and expand itself in Europe.

GelrinC is a biodegradable implant that increases growth of articular cartilage in damaged knee joints. The product is made of polyethylene glycol diacrylate and denatured fibrinogen developed at the Technion – Israel Institute of Technology by Dror Seliktar, PhD. It is currently undergoing clinical trials and is unavailable in the United States, Europe and Israel.

“With this new investment, Regentis is poised to expand its clinical efforts and further demonstrate how GelrinC can regenerate cartilage so patients can return to an active lifestyle,” Alastair J. Clemow, PhD, chief executive officer and president of Regentis Biomaterials, said in a company press release.